C4 Therapeutics : Our Corporate Presentation (caeeec)
CCCC
Published on 05/07/2025 at 07:40
Protein degraded. Disease targeted. Lives transformed.
May 2025
Our portfolio of degrader medicines pursues targets that may benefit from a degrader approach:
To deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients' lives.
Cemsidomide
targeting IKZF1/3 for multiple myeloma and non-Hodgkin's lymphoma
CFT8919
targeting EGFR L858R for non-small cell lung cancer
CFT19461
targeting BRAF V600 mutant for solid tumors including melanoma & colorectal cancer
targets in therapeutic areas in and beyond oncology with a strong degrader rationale and genetic link to disease
3
1CFT1946 Phase 1 trial is ongoing. C4T will not advance CFT1946 beyond the Phase 1 trial
C4T Has Been at the Forefront of TPD Science and Is On the Path to Becoming a Fully Integrated Biotechnology Company
MM cemsidomide data presented in December 2024 at ASH
Built TORPEDO platform to design highly catalytic, orally bioavailable degraders
Established collaborations with leading global pharmaceutical companies, building expertise across a range of diseases and target classes
Assembled strong catalog of intellectual property
Progressed four development candidates into the clinic with three clinical trials ongoing
Delivered two development candidates to a collaborator for non-oncology targets
Achieved blood-brain barrier penetration in several development candidates
Advancing clinical programs to approval for patients with high unmet needs
Leveraging TORPEDO platform to develop a sustainable pipeline against targets with a strong degrader rationale and genetic link to disease in therapeutic areas in and beyond oncology
Expanding application of targeted protein degradation through high-value collaborations
Focused Pipeline to Advance a Portfolio of Degrader Medicines Targeting Areas of High Unmet Need
EARLY
LATE
PROGRAM
TARGET
INDICATIONS
RESEARCH
PRECLINICAL
DEVELOPMENT
DEVELOPMENT
RIGHTS
Multiple Myeloma &
Non-Hodgkin's Lymphoma
MM NHL
CFT19462 BRAF V600
V600 Mutant Cancers
Colorectal Cancer Melanoma
Other BRAF V600 Mutant Cancers
indications
Discovery Programs Oncology & Non-oncology
1 License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China
2 In May 2025, C4T announced CFT1946 will not advance beyond Phase 1 and that the company will seek partnership for the BRAF program
Disclaimer
C4 Therapeutics Inc. published this content on May 07, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2025 at 11:39 UTC.